Fairmount Funds Management LLC has filed 99 insider transactions across 10 companies since July 2023.
Most recent transaction: a purchase of 150000 shares of Zenas BioPharma, Inc. ($ZBIO) on March 31, 2026.
Activity breakdown: 13 open-market purchases and 3 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | P | Common Stock | 150000 | $20.00 | 2,359,025.0000 | 44,730,052 | 6.79% | 0.34% |
| March 31, 2026 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Director | C | Common Stock | 7000000 | $0.00 | 12,503,418.0000 | 162,308,820 | 127.19% | 4.31% |
| March 31, 2026 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Director | C | Series A Convertible Preferred Stock | 28000 | $0.00 | 39,414.0000 | 162,308,820 | 41.53% | 0.02% |
| March 31, 2026 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Director | S | Common Stock | 7000000 | $34.66 | 5,503,418.0000 | 162,308,820 | 55.98% | 4.31% |
| March 23, 2026 | Damora Therapeutics, Inc. | $DMRA | Fairmount Funds Management LLC | Not found | A | Stock Option (right to buy) | 37313 | $0.00 | 37,313.0000 | 1,327,212 | 9999.99% | 2.81% |
| Feb. 9, 2026 | Damora Therapeutics, Inc. | $DMRA | Fairmount Funds Management LLC | Not found | M | Series C Preferred Stock | 2904 | $0.00 | 1,722.0000 | 1,327,212 | 62.78% | 0.22% |
| Feb. 9, 2026 | Damora Therapeutics, Inc. | $DMRA | Fairmount Funds Management LLC | Not found | M | Common Stock | 5809000 | $0.00 | 8,713,000.0000 | 1,327,212 | 200.03% | 100.00% |
| Feb. 9, 2026 | Damora Therapeutics, Inc. | $DMRA | Fairmount Funds Management LLC | Not found | M | Common Stock | 2904000 | $0.00 | 8,713,000.0000 | 1,327,212 | 49.99% | 100.00% |
| Feb. 9, 2026 | Damora Therapeutics, Inc. | $DMRA | Fairmount Funds Management LLC | Not found | M | Series C Preferred Stock | 5809 | $0.00 | 1,722.0000 | 1,327,212 | 77.13% | 0.44% |
| Jan. 22, 2026 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Director | S | Common Stock | 3500000 | $36.40 | 5,503,418.0000 | 142,376,529 | 38.87% | 2.46% |
| Jan. 22, 2026 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | S | Common Stock | 1750000 | $76.30 | 400,979.0000 | 68,320,229 | 81.36% | 2.56% |
| Dec. 4, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | Fairmount Funds Management LLC | Director | P | Pre-Funded Warrant (Right to Buy) | 131434 | $13.41 | 1,768,140.0000 | 13,892,516 | 8.03% | 0.95% |
| Dec. 4, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | Fairmount Funds Management LLC | Director | P | Ordinary Shares | 1360000 | $13.41 | 2,747,866.0000 | 13,892,516 | 97.99% | 9.79% |
| Oct. 23, 2025 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Director | P | Common Stock | 454545 | $22.00 | 3,914,458.0000 | 81,484,950 | 13.14% | 0.56% |
| Oct. 7, 2025 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | P | Common Stock | 316219 | $19.00 | 2,209,025.0000 | 42,159,340 | 16.71% | 0.75% |
| Oct. 6, 2025 | Jade Biosciences, Inc. | $JBIO | Fairmount Funds Management LLC | Director | A | Pre-Funded Warrant (Right to Buy) | 855047 | $9.14 | 855,047.0000 | 0 | 9999.99% | 0.00% |
| Oct. 6, 2025 | Jade Biosciences, Inc. | $JBIO | Fairmount Funds Management LLC | Director | A | Common Stock | 1333126 | $9.14 | 4,553,494.0000 | 0 | 41.40% | 0.00% |
| Sept. 17, 2025 | Oruka Therapeutics, Inc. | $ORKA | Fairmount Funds Management LLC | Director | A | Common Stock | 333340 | $15.00 | 3,705,262.0000 | 42,095,951 | 9.89% | 0.79% |
| July 10, 2025 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Director | P | Common Stock | 2777777 | $9.00 | 9,003,418.0000 | 113,850,090 | 44.62% | 2.44% |
| June 23, 2025 | CRESCENT BIOPHARMA, INC. | $CBIO | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 9023 | $0.00 | 9,023.0000 | 0 | 9999.99% | 0.00% |
| June 17, 2025 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 14461 | $0.00 | 28,922.0000 | 46,016,542 | 100.00% | 0.03% |
| June 17, 2025 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 14461 | $0.00 | 28,922.0000 | 46,016,542 | 100.00% | 0.03% |
| June 10, 2025 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 18500 | $0.00 | 18,500.0000 | 41,800,802 | 9999.99% | 0.04% |
| June 10, 2025 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Director | M | Stock Option (Right to Buy) | 12500 | $0.00 | 0.0000 | 81,484,950 | 100.00% | 0.02% |
| June 10, 2025 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Director | M | Common Stock | 12500 | $12.31 | 3,459,913.0000 | 81,484,950 | 0.36% | 0.02% |
| June 9, 2025 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Director | M | Stock Option (Right to Buy) | 1600 | $0.00 | 0.0000 | 81,484,950 | 100.00% | 0.00% |
| June 9, 2025 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Director | M | Common Stock | 1600 | $7.80 | 3,447,413.0000 | 81,484,950 | 0.05% | 0.00% |
| June 2, 2025 | Oruka Therapeutics, Inc. | $ORKA | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 17500 | $0.00 | 17,500.0000 | 41,679,560 | 9999.99% | 0.04% |
| May 29, 2025 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 25000 | $0.00 | 50,000.0000 | 60,275,561 | 100.00% | 0.04% |
| May 29, 2025 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 25000 | $0.00 | 50,000.0000 | 60,275,561 | 100.00% | 0.04% |
| April 29, 2025 | Jade Biosciences, Inc. | $JBIO | Fairmount Funds Management LLC | Not found | A | Stock Option (Right to Buy) | 23017 | $0.00 | 23,017.0000 | 0 | 9999.99% | 0.00% |
| Nov. 19, 2024 | Oruka Therapeutics, Inc. | $ORKA | Fairmount Funds Management LLC | Director | M | Common Stock | 160000 | $0.00 | 3,371,922.0000 | 15,013,655 | 4.98% | 1.07% |
| Nov. 19, 2024 | Oruka Therapeutics, Inc. | $ORKA | Fairmount Funds Management LLC | Director | M | Series A Non-Voting Convertible Preferred Stock | 160 | $0.00 | 0.0000 | 15,013,655 | 100.00% | 0.00% |
| Sept. 27, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Fairmount Funds Management LLC | Director | J | Common Stock | 62146 | $0.00 | 2,700,691.0000 | 0 | 2.25% | 0.00% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | P | Common Stock | 300000 | $17.00 | 1,892,806.0000 | 1,567,269 | 18.83% | 19.14% |
| Sept. 13, 2024 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Director | P | Common Stock | 1600000 | $18.75 | 3,445,813.0000 | 0 | 86.68% | 0.00% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Common Stock | 41130 | $0.00 | 329,045.0000 | 1,567,269 | 14.29% | 2.62% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Common Stock | 252890 | $0.00 | 581,935.0000 | 1,567,269 | 76.86% | 16.14% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Common Stock | 709794 | $0.00 | 1,291,729.0000 | 1,567,269 | 121.97% | 45.29% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Common Stock | 301077 | $0.00 | 1,592,806.0000 | 1,567,269 | 23.31% | 19.21% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Series Seed Convertible Preferred Stock | 357143 | $0.00 | 0.0000 | 1,567,269 | 100.00% | 22.79% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Series A Convertible Preferred Stock | 2195871 | $0.00 | 0.0000 | 1,567,269 | 100.00% | 100.00% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Series B Convertible Preferred Stock | 6163236 | $0.00 | 0.0000 | 1,567,269 | 100.00% | 100.00% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Series C Convertible Preferred Stock | 2614287 | $0.00 | 0.0000 | 1,567,269 | 100.00% | 100.00% |
| Sept. 12, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 37000 | $0.00 | 37,000.0000 | 1,567,269 | 9999.99% | 2.36% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Common Stock | 301077 | $0.00 | 1,304,891.0000 | 1,567,269 | 29.99% | 19.21% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Common Stock | 41130 | $0.00 | 41,140.0000 | 1,567,269 | 9999.99% | 2.62% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Common Stock | 252890 | $0.00 | 294,020.0000 | 1,567,269 | 614.86% | 16.14% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Common Stock | 709794 | $0.00 | 1,003,814.0000 | 1,567,269 | 241.41% | 45.29% |
| Sept. 12, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 37000 | $0.00 | 37,000.0000 | 1,567,269 | 9999.99% | 2.36% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Series C Convertible Preferred Stock | 2614287 | $0.00 | 0.0000 | 1,567,269 | 100.00% | 100.00% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Series B Convertible Preferred Stock | 6163236 | $0.00 | 0.0000 | 1,567,269 | 100.00% | 100.00% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Series A Convertible Preferred Stock | 2195871 | $0.00 | 0.0000 | 1,567,269 | 100.00% | 100.00% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | C | Series Seed Convertible Preferred Stock | 357143 | $0.00 | 0.0000 | 1,567,269 | 100.00% | 22.79% |
| Sept. 16, 2024 | Zenas BioPharma, Inc. | $ZBIO | Fairmount Funds Management LLC | Director | P | Common Stock | 300000 | $17.00 | 1,604,891.0000 | 1,567,269 | 22.99% | 19.14% |
| Sept. 11, 2024 | Oruka Therapeutics, Inc. | $ORKA | Fairmount Funds Management LLC | Director | A | Series A Non-Voting Convertible Preferred Stock | 160 | $23000.00 | 160.0000 | 3,197,975 | 9999.99% | 0.01% |
| Sept. 11, 2024 | Oruka Therapeutics, Inc. | $ORKA | Fairmount Funds Management LLC | Director | A | Common Stock | 275000 | $23.00 | 3,211,922.0000 | 3,197,975 | 9.36% | 8.60% |
| June 10, 2024 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Not found | M | Common Stock | 1500000 | $0.00 | 6,225,641.0000 | 0 | 31.74% | 0.00% |
| June 10, 2024 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Not found | M | Series B Convertible Preferred Stock | 1500 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| June 5, 2024 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 10370 | $0.00 | 10,370.0000 | 0 | 9999.99% | 0.00% |
| June 5, 2024 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 10370 | $0.00 | 10,370.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Fairmount Funds Management LLC | Not found | A | Stock Option (Right to Buy) | 11000 | $0.00 | 11,000.0000 | 0 | 9999.99% | 0.00% |
| May 14, 2024 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | A | Stock Option (Right to Buy) | 11323 | $0.00 | 22,646.0000 | 0 | 100.00% | 0.00% |
| May 14, 2024 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | A | Stock Option (Right to Buy) | 11323 | $0.00 | 22,646.0000 | 0 | 100.00% | 0.00% |
| April 25, 2024 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | M | Series A Preferred Stock | 90992 | $0.00 | 346,045.0000 | 0 | 20.82% | 0.00% |
| April 25, 2024 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | M | Common Stock | 3639680 | $0.00 | 4,830,177.0000 | 0 | 305.73% | 0.00% |
| March 28, 2024 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Not found | J | Series A Convertible Preferred Stock | 11914 | $0.00 | 67,414.0000 | 0 | 15.02% | 0.00% |
| March 28, 2024 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Not found | J | Series A Non-Voting Convertible Preferred Stock | 21999 | $0.00 | 133,191.0000 | 0 | 14.18% | 0.00% |
| March 28, 2024 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Not found | J | Common Stock | 5859 | $0.00 | 1,845,813.0000 | 0 | 0.32% | 0.00% |
| March 28, 2024 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Not found | J | Common Stock | 5859 | $0.00 | 1,845,813.0000 | 0 | 0.32% | 0.00% |
| April 1, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Fairmount Funds Management LLC | Not found | J | Common Stock | 58857 | $0.00 | 2,762,837.0000 | 0 | 2.18% | 0.00% |
| April 1, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Fairmount Funds Management LLC | Not found | J | Common Stock | 58857 | $0.00 | 2,762,837.0000 | 0 | 2.09% | 0.00% |
| March 28, 2024 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | J | Non-Voting Common Stock | 221426 | $0.00 | 6,743,321.0000 | 0 | 3.18% | 0.00% |
| March 28, 2024 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | J | Common Stock | 55913 | $0.00 | 2,150,979.0000 | 0 | 2.67% | 0.00% |
| March 28, 2024 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | J | Common Stock | 55913 | $0.00 | 2,150,979.0000 | 0 | 2.53% | 0.00% |
| March 28, 2024 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | J | Non-Voting Common Stock | 221426 | $0.00 | 6,743,321.0000 | 0 | 3.40% | 0.00% |
| March 28, 2024 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Not found | J | Common Stock | 286851 | $0.00 | 4,725,641.0000 | 0 | 5.72% | 0.00% |
| March 28, 2024 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Not found | J | Common Stock | 286851 | $0.00 | 4,725,641.0000 | 0 | 6.46% | 0.00% |
| March 28, 2024 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Not found | J | Series A Non-Voting Convertible Preferred Stock | 21999 | $0.00 | 133,191.0000 | 0 | 19.78% | 0.00% |
| March 28, 2024 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Not found | J | Series A Convertible Preferred Stock | 11914 | $0.00 | 67,414.0000 | 0 | 21.47% | 0.00% |
| Feb. 16, 2024 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Not found | A | Series B Convertible Preferred Stock | 1500 | $7500.00 | 1,500.0000 | 0 | 9999.99% | 0.00% |
| Feb. 16, 2024 | Cogent Biosciences, Inc. | $COGT | Fairmount Funds Management LLC | Not found | A | Common Stock | 1166666 | $7.50 | 4,725,641.0000 | 0 | 32.78% | 0.00% |
| Jan. 29, 2024 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | J | Common Stock | 892529 | $0.00 | 102,332.0000 | 0 | 89.71% | 0.00% |
| Jan. 29, 2024 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | J | Common Stock | 51166 | $0.00 | 102,332.0000 | 0 | 100.00% | 0.00% |
| Jan. 29, 2024 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | J | Common Stock | 51166 | $0.00 | 102,332.0000 | 0 | 100.00% | 0.00% |
| Jan. 22, 2024 | Viridian Therapeutics, Inc.\DE | $VRDN | Fairmount Funds Management LLC | Not found | P | Common Stock | 476190 | $21.00 | 1,845,813.0000 | 0 | 34.77% | 0.00% |
| Jan. 22, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Fairmount Funds Management LLC | Not found | A | Common Stock | 834334 | $12.00 | 2,762,837.0000 | 0 | 43.26% | 0.00% |
| Jan. 22, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | Fairmount Funds Management LLC | Not found | A | Pre-Funded Warrants (Right to Buy) | 832333 | $12.00 | 832,333.0000 | 0 | 9999.99% | 0.00% |
| Dec. 29, 2023 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | J | Common Stock | 406038 | $0.00 | 1,190,497.0000 | 0 | 51.76% | 0.00% |
| Dec. 29, 2023 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | J | Common Stock | 3435480 | $0.00 | 1,190,497.0000 | 0 | 74.26% | 0.00% |
| Dec. 29, 2023 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | J | Common Stock | 406038 | $0.00 | 1,190,497.0000 | 0 | 51.76% | 0.00% |
| Dec. 7, 2023 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | A | Series B Preferred Stock | 16667 | $600.00 | 16,667.0000 | 0 | 9999.99% | 0.00% |
| Nov. 24, 2023 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | C | Common Stock | 3435480 | $0.00 | 3,813,901.0000 | 0 | 907.85% | 0.00% |
| Nov. 24, 2023 | Spyre Therapeutics, Inc. | $SYRE | Fairmount Funds Management LLC | Not found | C | Series A Preferred Stock | 85887 | $0.00 | 437,037.0000 | 0 | 16.42% | 0.00% |
| July 13, 2023 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 47758 | $0.00 | 47,758.0000 | 0 | 9999.99% | 0.00% |
| July 13, 2023 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | P | Common Stock | 892529 | $17.00 | 2,941,176.0000 | 0 | 43.57% | 0.00% |
| July 13, 2023 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | P | Common Stock | 1992734 | $17.00 | 2,941,176.0000 | 0 | 210.11% | 0.00% |
| July 13, 2023 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | P | Common Stock | 55913 | $17.00 | 2,941,176.0000 | 0 | 1.94% | 0.00% |
| July 13, 2023 | Apogee Therapeutics, Inc. | $APGE | Fairmount Funds Management LLC | Director | A | Stock Option (Right to Buy) | 47758 | $0.00 | 47,758.0000 | 0 | 9999.99% | 0.00% |